vTv Therapeutics Announces First Study Participant Randomized in CATT1 Phase 3 Trial of Cadisegliatin in Type 1 Diabetes

Core Insights - vTv Therapeutics Inc. has initiated the CATT1 Phase 3 trial for cadisegliatin, an oral glucokinase activator for type 1 diabetes, with topline results expected in the second half of 2026 [1][2] - The trial aims to enroll approximately 150 participants across 25 sites in the U.S., evaluating the efficacy and safety of cadisegliatin compared to placebo [2][4] - Cadisegliatin has received Breakthrough Therapy designation from the FDA and has shown good tolerability in over 500 subjects [1][2] Company Overview - vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral small molecule drug candidates for diabetes and other chronic diseases [6] - The company's lead program, cadisegliatin, is being investigated as a potential first-in-class oral adjunctive treatment for type 1 diabetes [6] Industry Context - There is a significant unmet need for therapeutic advances in type 1 diabetes, as current medical devices have not been complemented by effective oral adjunct therapies [2][3] - The introduction of glucokinase activators like cadisegliatin could potentially improve glycemic control while reducing the risks of hypoglycemia and diabetic ketoacidosis [3][4]